Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from RCM-1 human colorectal cancer cells treated with methylthioacetic acid

ABSTRACT: Methylthioacetic acid (MTA) is thought to potentially have an anticancer activity because it promotes the differentiation of unorganized cell mass into dome tissues in RCM-1 human colorectal cancer cell line. To elucidate a molecular mechanism underlying MTA-mediated dome formation, we used microarrays to disclose the global changes in gene expression caused by MTA and define the candidate genes involved in this phenomenon.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139279 | GEO | 2020/10/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from RCM-1 human colorectal cancer cells treated with methylthioacetic acid

Project description:Expression data from RCM-1 human colorectal cancer cells treated with methylthioacetic acid

| PRJNA579084 | ENA

Phenylacetaldehyde inhibits development of colorectal cancer

Project description:Phenylacetaldehyde (PAA), a product of phenylalanine metabolism, is catabolized by microbiota and has demonstrated anticancer properties in breast cancer. As intestinal homeostasis is influenced by gut microbiome, we investigated the effect of PAA on colorectal cancer (CRC). In the study, we interrogated the mechanistic pathways induced by PAA treatment using RNA sequencing.

2023-07-11 | GSE207618 | GEO

Expression data of colorectal cancer HT-29 cells

Project description:Colorectal cancer HT-29 cell line is a comonly-used human cancer cell line. We have used this cell line for examining the effect of various anticancer compounds on gene expression and we obtained gene expression data of untreated HT-29 cells as a control data for the analysis.

2017-06-14 | GSE99968 | GEO

Global gene expression profiling of human colorectal cancer cell lines

Project description:The development of anticancer drugs relies on preclinical models closely recapitulating the molecular profile observed patients. We report here the transcriptional profiles of 155 stable cell lines derived from colorectal cancer and related tissues. For these lines, also mutational and pharmacological profiles are available, which enables their stratification into clinically relevant subgroups.

2015-06-01 | GSE59857 | GEO

hepatocellular carcinoma vs. corresponding noncancerous liver or normal liver

Project description:Hepatocellular carcinoma (HCC) remains a major health problem worldwide, and HCC patients have a poor prognostic outcome. In this study, we systematically disclose mechanisms of hepatocarcinogenesis, and also effectively identify and validate novel anticancer targets in HCCs. Keywords: disease state analysis

2009-01-06 | GSE4108 | GEO

Genomic editing of pathogenic TNNI3 mutation in restrictive cardiomyopathy rescues diastolic dysfunction of human induced pluripotent stem cell-derived cardiomyocytes

Project description:To investigate the physiological characteristics of cardiomyocytes (CM) in restrictive cardiomyopathy (RCM), we established RCM(heterozygous)-iPSC and produced RCM(homozygous)-iPSC and corrected Isogenic-iPSC using CRISPER-CAS9 technology. Then, we used the RNA-seq data obtained from these three iPSCs and three different healthy iPSC-derived CMs for gene expression profiling analysis.

2023-08-21 | GSE240775 | GEO

Epigenetically Down-Regulated BRCA2 through Acetyltransferase KAT2B Increases the Sensitivity of Colorectal Cancer to Olaparib

Project description:The clinical application of anticancer drugs depends on preclinical models closely recapitulating the molecular profile. We report here the transcriptional profiles of HCT116 (colorectal cancer cells) treated with DMSO or Olaparib for 24 hours. For these two different treatments, also changes of molecule expression are available, which enables their stratification into drug-therapeuticly relevant molecule.

2023-12-14 | GSE246781 | GEO

The effects of naltrexone on gene expression in HCT116 colorectal cancer cell line

Project description:A number of reports have identified a putative anticancer role for naltrexone when used at doses lower than those conventionally administered. In particular, it has been shown that these low doses of naltrexone are able to suppress tumour growth. A definitive mechanism of action has yet to be established, but what is known is that the effect can be via modifications to the host immune system rendering it more anticancer in nature, or through direct antagonism of tumour growth. Our current paper uses gene expression as a way of unraveling this.The human colorectal cancer cell line HCT116 was cultured in medium alone, or with naltrexone at two different doses for 4 hours. Cells were either harvested after this time or transferred into fresh medium for a further 24 hours before being harvested. RNA was isolated from these cells by Trizol. Total RNA was labelled and hybridised to Illumina Human HT-12v4 arrays.

2016-06-01 | E-MTAB-4454 | biostudies-arrayexpress

YTHDF3 improves translation initiation of mRNAs with N6-methyladenosine methylation at 5’ untranslated region by facilitating eIF2AK2 recruitment in oxaliplatin-resistant colorectal cancer

Project description:Oxaliplatin as a first-line drug frequently causes the chemo-resistance on colorectal cancer (CRC). N6-methyladenosine (m6A) methylation has been largely acknowledged in multiple biological functions. However, the molecular mechanisms underlying the m6A methylation in modulating anticancer drug resistance in CRC are still obscure. In present study, RNA-seq was conducted to investigate the transcriptome of CRC tissues from three patients at different disease stages (CapeOx combined chemotherapy sensitivity and resistance).

2022-02-05 | E-MTAB-11323 | biostudies-arrayexpress

Elemonic acid inhibits colorectal cancer

Project description:Quantitative proteomic analysis reveals β-elemonic acid inhibiting colorectal cancer targeting tumor mitochondria and triggering ferroptosis

2021-08-10 | PXD027833 | iProX

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data